
ImmunoMind is an open-source ecosystem for designing personalized immunotherapies and vaccines. Leveraging systems immunology, the platform focuses on therapy efficacy prediction by deciphering drug-immune system interactions, patient stratification and monitoring using multi-omics biomarkers, and immune cell-based biomarker discovery from single-cell and bulk multi-omics data. It aims to de-risk immunotherapy discovery for biotech startups, improve efficacy for immunotherapy biopharma, and fuel discovery for research groups by providing AI and bioinformatics capabilities. The company originated from UC Berkeley SkyDeck and Next Sequence.

ImmunoMind is an open-source ecosystem for designing personalized immunotherapies and vaccines. Leveraging systems immunology, the platform focuses on therapy efficacy prediction by deciphering drug-immune system interactions, patient stratification and monitoring using multi-omics biomarkers, and immune cell-based biomarker discovery from single-cell and bulk multi-omics data. It aims to de-risk immunotherapy discovery for biotech startups, improve efficacy for immunotherapy biopharma, and fuel discovery for research groups by providing AI and bioinformatics capabilities. The company originated from UC Berkeley SkyDeck and Next Sequence.
What they do: Open-source AI/bioinformatics platform for designing personalized immunotherapies and vaccines using single-cell and multi-omics data
Founded: 2020
HQ: Berkeley, California (also legal entity in Warsaw, Poland)
Founders: Sergey Fedyushchenko; Vadim Nazarov; Vasily Tsvetkov
Funding: Multiple early-stage rounds; latest listed Pre-Seed Jan 1, 2022; total reported ~$755,000
Immunotherapy and vaccine discovery, biomarker discovery, and patient stratification using single-cell and multi-omics data.
2020
Biotechnology
Latest listed round per public profiles
“SkyDeck Berkeley listed as investor/accelerator supporter”